Brief: Alphamab Oncology Says Loss For Year RMB325.7 Million
31/03/2023 16:11
March 31 (Reuters) - Alphamab Oncology 9966.HK :
* LOSS FOR YEAR RMB325.7 MILLION VERSUS LOSS RMB412.4
MILLION
* FY REVENUE RMB166.8 MILLION VERSUS RMB146.0 MILLION
Source text for Eikon: ID:nHKS29M43M
Further company coverage: 9966.HK
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)